Todd Shriber

Todd Shriber

InvestorPlace Contributor

Recent Articles

5 Emerging Markets ETFs to Consider as 2020 Rebound Plays

By Todd Shriber, InvestorPlace Contributor

The coronavirus is weighing on emerging markets assets, but it's not all gloom and doom. These standout ETFs could be ready to rally in 2020.

Dow Jones Today: A Day for Safe Havens

By Todd Shriber, InvestorPlace Contributor

It was a sluggish day for stocks to close the week as Dow components struggled to find noteworthy gains today on light volume.

Dow Jones Today: Coronavirus Controversy Reemerges

By Todd Shriber, InvestorPlace Contributor

Stocks traded lower Thursday as more coronavirus cases emerged while the Dow was held back by a big loss by Cisco.

Even If Cannabis Recovers, Aurora Stock Is a Terrible Bet

By Todd Shriber, InvestorPlace Contributor

That's one way of saying Aurora is again proving to be a value destroyer. Another way of saying that is that stock is down a staggering 78.52% over the past 12 months. It's not uncommon for companies that experience equity market depreciation on par with Aurora to have cash problems and that's exactly what the Canadian cannabis company is facing.

Is the Bad News Already Baked into Boeing Stock? Maybe

By Todd Shriber, InvestorPlace Contributor

It wasn't just issues surrounding the 737 Max jet that stymied Boeing stock last year, though that was the primary reason. Derivative woes, including internal cultural problems that became apparent as the year went along held back BA stock.

Dow Jones Today: Easing Coronavirus Concerns Propel Stocks Higher

By Todd Shriber, InvestorPlace Contributor

UnitedHealth was an epic winner for the Dow Jones today, but that big pop requires more examination. Here's why.

Apple Stock Won’t Move up in a Straight Line, but It’s Still a Buy

By Todd Shriber, InvestorPlace Contributor

For fans of such anecdotes, a $100 investment in Apple in 2010 was worth more than $1,100 at the end of 2019. That's obviously a stellar return, but it should not imply that Apple is done delivering for investors. Yes, there will be bumps along the way and asking Apple to be worth $2.8 trillion at this time next year is asking a lot, but betting against Tim Cook and team is a risky proposition at best.

Dow Jones Today: China-Sensitive Names Lead the Way

By Todd Shriber, InvestorPlace Contributor

Gains were modest as tech stocks were pinched by news that the FTC is planning to review old deals by Apple, Microsoft and others.

There’s No Miraculous Comeback Looming for Acasti Pharma Stock

By Todd Shriber, InvestorPlace Contributor

Acasti's Phase 3 trial of CaPre, aimed at patients with high levels of triglycerides, isn't working out, explaining why the stock is down 69.11% to start 2020. One of the primary causes of concern with the Trilogy 1 Phase 3 trial of CaPre was that there were unanticipated levels of placebo response. Said another way, patients got a cornstarch pill, which of course would be far less expensive than any drug, and had a positive reaction to it.

Dow Jones Today: Stocks Shrug Off Q1 GDP Warning

By Todd Shriber, InvestorPlace Contributor

Stocks pushed higher again today with broad-based contributions, even though a tepid first-quarter GDP estimate was published this morning.

Load More